A review of levosimendan in the treatment of heart failure

References

• AbrahamWTAdamsKFFonarowGCIn-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications. An analysis from the acute decompensated heart failure national registry (ADHERE)J Am Coll Cardiol200546576415992636
   PubMed Web of Science ®Google Scholar
• AntilaSEhaJHeinpaluMHaemodynamic interactions of a new calcium sensitizing drug levosi-mendanand captoprilEur J Clin Pharmacol19964945188706769
   PubMed Web of Science ®Google Scholar
• AvgeropoulouCAndreadouISophia Markantonis-KyroudisTThe Ca 2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamineEur J Heart Fail20057882715921958
   PubMed Web of Science ®Google Scholar
• BolliRMechanism of myocardial ‘stunning’Circulation199082723382203553
   PubMed Web of Science ®Google Scholar
• BolliRMarbanEMolecular and cellular mechanisms of myocardial stunningPhysiol Rev1999796093410221990
   PubMed Web of Science ®Google Scholar
• BristowMRKrause-SteinraufHNuzzoREffect of baseline or changes in adrenergic activity on clinical outcomes in the β blocker evaluation of survival trialCirculation200411014374215337700
   PubMed Web of Science ®Google Scholar
• ChengVKazanagraRGarciaAA rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot studyJ Am Coll Cardiol2001373869111216951
   PubMed Web of Science ®Google Scholar
• ClelandJGFKhandAClarkAThe heart failure epidemic: exactly how big is it?Eur Heart J200122623611286518
   PubMed Web of Science ®Google Scholar
• ClelandJGFNikitinNMcGowanJLevosimendan: first in a new class of inodilator for acute and chronic severe heart failureExpert Rev Cardiovasc Ther2004291915038409
   PubMedGoogle Scholar
• CohnJNLevineTBOlivariMTPlasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failureN Engl J Med1984311819236382011
   PubMed Web of Science ®Google Scholar
• CodyRJDo positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I: introductionJ Am Coll Cardiol198812559613392348
   PubMed Web of Science ®Google Scholar
• CowieMRFoxKFWoodDASurvival of patients with a new diagnosis of heart failure: a population based studyHeart2000835051010768897
   PubMed Web of Science ®Google Scholar
• ColucciWSWrightRFBraunwaldENew positive inotropic agents in the treatment of congestive heart failure: mechanisms of action and recent clinical developmentsN Engl J Med1986314349582418353
   PubMed Web of Science ®Google Scholar
• De LucaLColucciWSNieminenMSEvidence-based use of levosimendan in different clinical settingsEur Heart2006 J, Apr 27; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• De LucaLProiettiPCelottoALevosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunctionAm Heart J2005150563816169341
   PubMed Web of Science ®Google Scholar
• Delle KarthGBuberlAGeppertAHemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholaminesActa Anaesthesiol Scand20034712515614616323
   PubMed Web of Science ®Google Scholar
• DiesFKrellMJWhitlowPIntermittent dobutamine in ambulatory outpatients with chronic cardiac failureCirculation198674Suppl 23893524896
   PubMedGoogle Scholar
• FelkerGMBenzaRLChandlerABHeart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF studyJ Am Coll Cardiol200341997100312651048
   PubMed Web of Science ®Google Scholar
• FerrickKJFeinSAFerrickAMEffect of milrinone on ventricular arrhythmias in congestive heart failureAm J Cardiol19906643142386119
   PubMed Web of Science ®Google Scholar
• FrancoFGonçalvesFCastroGLevosimendan is efficacious in acute heart failure independent of renal function (abstract)Eur Heart J200324Suppl408
   Google Scholar
• FollathFClelandJGJustHEfficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialLancet200236019620212133653
   PubMed Web of Science ®Google Scholar
• GarrattCPackerMColucciWDevelopment of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study. (Abstract)Crit Care20048Suppl 18915025763
   PubMedGoogle Scholar
• GheorghiadeMTeerlinkJRMebazaaAPharmacology of New Agents for Acute Heart Failure SyndromesAm J Cardiol2005966873
   Web of Science ®Google Scholar
• GruhnNNielsen-KudskJETheilgaardSCoronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing propertiesJ Cardiovasc Pharmacol19983174199593074
   PubMed Web of Science ®Google Scholar
• GullestadLAassHFjeldJGImmunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failureCirculation2001103220511208680
   PubMed Web of Science ®Google Scholar
• HaikalaHLindenIBMechanisms of action of calcium-sensitizing drugsJ Cardiovasc Pharmacol199526S10198907127
   PubMed Web of Science ®Google Scholar
• HaikalaHPolleselloPCalcium sensitivity enhancersDrugs200031199205
   PubMedGoogle Scholar
• HaikalaHKaheinenPLevijokiJThe role of cAMP and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendanCardiovasc Res199734536469231037
   PubMed Web of Science ®Google Scholar
• HarkinCPPagelPSTessmerJPSystemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogsJ Cardiovasc Pharmacol199526179887475041
   PubMed Web of Science ®Google Scholar
• HasenfussGHolubarschCHeissHWMyocardial energetics in patients with dilated cardiomyopathyCirculation19898051642525432
   PubMed Web of Science ®Google Scholar
• HasenfussGPieskeBCastellMInfluence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardiumCirculation199898214179815868
   PubMed Web of Science ®Google Scholar
• HasenfussGPieskeBKretschmannBEffects of calcium sensitizers on intracellular calcium handling and myocardial energeticsJ Cardiovasc Pharmacol199526Suppl 1S45518907130
   PubMedGoogle Scholar
• JamaliINKerstenJRPagelPSIntracoronary levosimendan enhances contractile function of stunned myocardiumAnesth Analg1997852399212117
   PubMed Web of Science ®Google Scholar
• JanssenPMDatzNZeitzOHasenfussGLevosimendan improves diastolic and systolic function in failing human myocardiumEur J Pharmacol2000404191910980279
   PubMed Web of Science ®Google Scholar
• JohanssonSApajasaloMSarapohjaTEffect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I studyCrit Care20048Suppl 188
   Google Scholar
• KaheinenPPolleselloPLevijokiJLevosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channelsJ Cardiovasc Pharmacol2001373677411300649
   PubMed Web of Science ®Google Scholar
• KasikciogluHAUnalSTartanZEffects of levosimendan on left ventricular functional remodelling and exercise 1´ntolerance: a tissue doppler studyJ Int Med Res20053339740516104443
   PubMed Web of Science ®Google Scholar
• KayeDMLefkovitsJJenningsGLAdverse consequences of high sympathetic nervous activity in the failing human heartJ Am Coll Cardiol1995261257637594040
   PubMed Web of Science ®Google Scholar
• KaheinenPPolleselloPLevijokiJLevosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channelsJ Cardiovasc Pharmacol2001373677411300649
   PubMed Web of Science ®Google Scholar
• KivikkoMAntilaSEhaJPharmacokineticsof levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failureInt J Clin Pharmacol Ther2002a404657112395979
   PubMed Web of Science ®Google Scholar
• KivikkoMAntilaSEhaJPharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failureJ Clin Pharmacol2002b42435111808823
   PubMed Web of Science ®Google Scholar
• KivikkoMLehtonenLColucciWSSustained hemodynamic effects of intravenous levosimendanCirculation200310781612515747
   PubMed Web of Science ®Google Scholar
• KopustinskieneDMPolleselloPSarisNELevosimendan is a mitochondrial K(ATP) channel openerEur J Pharmacol20014283111411689188
   PubMed Web of Science ®Google Scholar
• KyrzopoulosSAdamopoulosSParissisJTLevosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patientsInt J Cardiol2005994091315771921
   PubMed Web of Science ®Google Scholar
• LeeJCDowningSECyclic AMP and the pathogenesis of myocardial injuryRes Commun Chem Pathol Pharmacol198027305186245436
   PubMedGoogle Scholar
• LehmannALangJBoldtJLevosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case seriesMed Sci Monit200410MT89MT9315278007
   PubMed Web of Science ®Google Scholar
• LehtonenLMills-OwensPAkkilaJSafety of levosimendan and other calcium sensitizersJ Cardiovasc Pharmacol199526Suppl 1706
   Google Scholar
• LevineBKalmanJMayerLElevated circulating levels of tumor necrosis factor in severe chronic heart failureN Engl J Med1990323236412195340
   PubMed Web of Science ®Google Scholar
• LillebergJNieminenMSAkkilaJEffects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass graftingEur Heart J19981966089597417
   PubMed Web of Science ®Google Scholar
• McMurrayJJStewartSEpidemiology, aetiology, and prognosis of heart failureHeart20008359660210768918
   PubMed Web of Science ®Google Scholar
• McMurrayJPfefferMANew therapeutic options in congestive heart failure: Part IICirculation20021052223811994259
   PubMed Web of Science ®Google Scholar
• McKeePACastelliWPMcNamaraPMThe natural history of congestive heart failure: The Framingham studyN Engl J Med1971285144165122894
   PubMed Web of Science ®Google Scholar
• MaytinMColucciWSCardioprotection: A new paradigm in the management of acute heart failure syndromesAm J Cardiol200596Suppl26G31G
   PubMedGoogle Scholar
• MebazaaAThe SURVIVE-W trial: comparison of dobutamine and levosimendan on survival in acutely decompensated heart failure2005 American Heart Association Scientific Sessions, Dallas, TX, November 16 2005
   Google Scholar
• MebazaaABarraudDWelschbilligSRandomized clinical trials with levosimendanAm J Cardiol200596Suppl74G79G15979438
   PubMedGoogle Scholar
• MichaelsADMcKeownBKostalMEffects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptakeCirculation20051111504915781741
   PubMed Web of Science ®Google Scholar
• MoertlDBergerRHuelsmannMShort-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failureEur J Heart Fail2005711566316084762
   PubMed Web of Science ®Google Scholar
• MoiseyevVSPoderPAndrejevsNSafety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN)Eur Heart J20022314223212208222
   PubMed Web of Science ®Google Scholar
• MosterdAHoesAWde BruyneMCPrevalence heart failure and left ventricular dysfunction in the general populationEur Heart J1999204475510213348
   PubMed Web of Science ®Google Scholar
• NanasJNPapazoglouPTerrovitisJVHemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine aloneAm J Cardiol20049413293215541261
   PubMed Web of Science ®Google Scholar
• NanasJNPapazoglouPTsagalauEPEfficacy and safety of intermittent, long-term,concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine aloneAm J Cardiol2005957687115757608
   PubMed Web of Science ®Google Scholar
• NieminenMSAkkilaJHasenfussGHemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failureJ Am Coll Cardiol20003619031211092663
   PubMed Web of Science ®Google Scholar
• NieminenMSBohmMCowieMRThe Task Force on Acute Heart Failure of the European Society of Cardiology. Executive summary of the guidelines on the diagnosis and treatment of acute heart failureEur Heart J20052638441615681577
   PubMed Web of Science ®Google Scholar
• NicklasJMMonsurJCBleskeBEEffects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic responseAm J Cardiol199983I12I15
   Web of Science ®Google Scholar
• O’RourkeBEvidence for mitochondrial K+ channels and their role in cardioprotectionCirc Res2004944203215001541
   PubMed Web of Science ®Google Scholar
• PackerMThe search for the ideal positive inotropic agentN Engl J Med199332920128515793
   PubMed Web of Science ®Google Scholar
• PackerMREVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure2005 American Heart Association Scientific Sessions, Dallas, TX, November 14 2005
   Google Scholar
• PackerMLeierCVSurvival in congestive heart failure during treatment with drugs with positive inotropic actionsCirculation198775Suppl 45563
   Google Scholar
• PagelPSMcGoughMFHettrickDALevosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathyJ Cardiovasc Pharmacol199729563739213196
   PubMed Web of Science ®Google Scholar
• ParissisJTAdamopoulosSAntoniadesCEffects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failureAm J Cardiol20049313091215135713
   PubMed Web of Science ®Google Scholar
• ParissisJTPanouFFarmakisDEffects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failureAm J Cardiol2005964232616054474
   PubMed Web of Science ®Google Scholar
• PatariczaJHohnJPetriAComparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan,in human isolated portal veinJ Pharm Pharmacol2000522131710714952
   PubMed Web of Science ®Google Scholar
• PerroneSVKaplinskyEJCalcium sensitizer agents: A new class of inotropic agents in the treatment of decompensated heart failureInt J Cardiol20051032485516098385
   PubMed Web of Science ®Google Scholar
• PlenzGSongZFTjanTDTActivation of the cardiac interleukin-6 system in advanced heart failureEur J Heart Fail200134152111511426
   PubMed Web of Science ®Google Scholar
• RossigLFichtlschererSHeeschenCThe pro-apoptotic serum activity is an independent mortality predictor of patients with heart failureEur Heart J2004251620515351161
   PubMed Web of Science ®Google Scholar
• SandellEPWesby-van SwaayEPõderPA meta-analysis on the safety of the calcium sensitizing agent levosimendan2004Heart Failure Update Meeting (European Society of Cardiology)June 12–15 2004Wroclaw, Poland
   Google Scholar
• SasayamaSMatsumoriAKiharaYNew insights into the pathophysiological role for cytokines in heart failureCardiovasc Res1999425576410533591
   PubMed Web of Science ®Google Scholar
• SetaYShanKBozkurtBBasic mechanisms in heart failure: the cytokine hypothesisJ Card Fail1996324398891862
   PubMedGoogle Scholar
• SlawskyMTColucciWSGottliebSSfor the Study InvestigatorsAcute hemodynamic and clinical effects of levosimendan in patients with severe heart failureCirculation20001022222711056096
   PubMed Web of Science ®Google Scholar
• SinghBNLillebergJSandellEPEffects of levosimendan on cardiac arrhythmia: Electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failureAm J Cardiol1999831620
   Web of Science ®Google Scholar
• SkudickyDBergemannASliwaKBeneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilolCirculation20011031083811222470
   PubMed Web of Science ®Google Scholar
• SoeiLKSassenLMFanDSMyofibrillar Ca2+ sensitization predominantly enhances function and mechanical efficiency of stunned myocardiumCirculation199490959698044968
   PubMed Web of Science ®Google Scholar
• SonntagSSundbergSLehtonenLAThe calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemiaJ Am Coll Cardiol20044321778215193677
   PubMed Web of Science ®Google Scholar
• SundbergSAntilaSScheininHIntegrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assesed by systolic time intervalsInt J Clin Pharmacol Ther199836629359876999
   PubMed Web of Science ®Google Scholar
• SundbergSLehtonenLHaemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjectsEur J Clin Pharmacol200055793910805056
   PubMed Web of Science ®Google Scholar
• SuttonGCEpidemiologic aspects of heart failureAm Heart J19901201538402248209
   PubMed Web of Science ®Google Scholar
• TachibanaHChengHUkaiTLevosimendan improves left ventricular systolic and diastolic performance at rest and during exercise after heart failureAm J Physiol Heart Circ Physiol2005288H914H92215486041
   PubMed Web of Science ®Google Scholar
• ToivonenLViitasaloMSundbergSElectrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac functionJ Cardiovasc Pharmacol200035664910774799
   PubMed Web of Science ®Google Scholar
• Torre-AmioneGKapadiaSBenedictCProinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD)J Am Coll Cardiol199627120168609343
   PubMed Web of Science ®Google Scholar
• TsutamotoTHisanagaTWadaAInterleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failureJ Am Coll Cardiol19983139189462584
   PubMed Web of Science ®Google Scholar
• TziakasDNChalikiasGKHatzinikolaouHILevosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failureCardiovasc Drugs Ther20051939940216435069
   PubMed Web of Science ®Google Scholar
• UkkonenHSarasteMAkkilaJMyocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteersClin Pharmacol Ther1997615966079164421
   PubMed Web of Science ®Google Scholar
• UkkonenHSarasteMAkkilaJMyocardial efficiency during levosimendan infusion in congestive heart failureClin Pharmacol Ther2000685223111103755
   PubMed Web of Science ®Google Scholar
• YokoshikiHKatsubeYSunagawaMLevosimendan, a novel Ca 2 sensitizer, activates the glibenclamide-sensitive K-channel in rat arterial myocytesEur J Pharmacol1997333249599314042
   PubMed Web of Science ®Google Scholar
• YokoshikiHSperelakisNVasodilating mechanism of levosimendanCardiovasc Drugs Ther2003171111314562823
   PubMed Web of Science ®Google Scholar
• ZairisMNApostolatosCAnastassiadisFComparison of the effect of levosi-mendan,or dobutamine or placebo in chronic low output decompen-sated heart failure. CAlcium Sensitizer or Inotrope or NOne in low output heart failure (CASINO) study2004Program and abstracts of the European Society of Cardiology, Heart Failure Update2004; June 12–15Wroclaw, Poland
   Google Scholar